Coalition to Cure Calpain 3 (C3) is pleased to announce that Dr. Stefanie Müthel was awarded a Travel Grant for the presentation of her research at the Biology of Calpains in Health and Disease Conference in Pacific Grove, California, from July 14-19, 2019. Dr. Müthel is a postdoctoral researcher in the laboratory of Dr. Simone Spuler at…
Read MoreDefining Clinical Endpoints in LGMD
Coalition to Cure Calpain 3 (C3) is pleased to announce that a research grant has been awarded to Dr. Nicholas Johnson, Associate Professor & Vice Chair of Research, Virginia Commonwealth University. The project is titled “Defining Clinical Endpoints in LGMD.” What are COAs, and why do they matter to those living with LGMD? Clinical outcome assessments (COAs)…
Read MoreC3 Hosts Gene Therapy for LGMD2A Workshop
Coalition to Cure Calpain 3 (C3) is committed to treating and ultimately curing limb-girdle muscular dystrophy, type 2A (LGMD2A), a form of calpainopathy. C3’s mission is to fund therapeutically relevant research and clinical trials as we educate the global community about this disease. Gene replacement in this primary calpainopathy (CAPN3) is currently the most direct path…
Read MoreC3 Awards Research Grant to Dr. Jaakko Sarparanta to Investigate Relationship Between Calpain 3 Activity and the Protein Titin
C3 SUPPORTS RESEARCH GROUP FOR NEUROMUSCULAR DISEASES Coalition to Cure Calpain 3 (C3) is pleased to announce that a research grant has been awarded to Dr. Jaakko Sarparanta, researcher at the Research Group for Neuromuscular Diseases led by Dr. Bjarne Udd at Folkhälsan Research Center and Department of Medical Genetics, University of Helsinki, Finland. The project, titled “CAPN3-mediated proteolytic processing of…
Read MoreNew report confirms calpainopathy is most common type of LGMD
A paper recently published by Madhuri Hegde, Emory University, and colleagues analyzed the outcomes of genetically sequencing a large group of patients with limb girdle weakness in the United States. This study is unique in that it included a very large cohort of patients – 4656 – who were enrolled in the Muscular Dystrophy Association…
Read MoreC3 Scientific Conference 2018
On September 12 – 13, 2018, Coalition to Cure Calpain 3 hosted the “C3 Scientific Conference” in Arlington, Virginia. In attendance were prominent neuromuscular clinicians, world renowned research scientists from academia and industry, and representatives from various funding agencies. This included C3’s Scientific Advisory Board and C3 grant recipients. The goal of the conference was…
Read MoreC3 Presents at World Muscle Society Congress
Coalition to Cure Calpain 3 (C3) attended the 23rd International Annual Congress of the World Muscle Society, October 2-6 2018 in Mendoza, Argentina. Dr. Jennifer Levy, C3 Scientific Director, represented C3 and presented a poster detailing our mission, registry, and research grants program. Attendees include neuromuscular clinicians, academics, research scientists, and industry leaders from around the…
Read MoreCoalition to Cure Calpain 3 Provides Gene Therapy Initiative Updates
Two new research projects funded to explore potential treatments for calpainopathy/LGMD2A $500,000+ committed to gene therapy research since initiative launched in 2017 Coalition to Cure Calpain 3 (C3), a non-profit patient advocacy organization focused on identifying and advancing potential treatments for limb-girdle muscular dystrophy type 2A/calpainopathy (LGMD2A), today announced updates to its Gene Therapy Initiative….
Read MoreC3 Awards Gene Therapy Initiative Grant to Dr. Zarife Sahenk
FOURTH GENE THERAPY INITIATIVE GRANT SUPPORTS PROMISING RESEARCH AT NATIONWIDE CHILDREN’S HOSPITAL Coalition to Cure Calpain 3 (C3) is excited to announce that a new research grant has been awarded to Dr. Zarife Sahenk, Professor of Pediatrics and Neurology at Nationwide Children’s Hospital, to assess the safety and efficacy of adeno-associated viral (AAV)-mediated gene therapy in a mouse model…
Read MoreCoalition to Cure Calpain 3 Awards Grant to Dr. Kathryn Wagner
Coalition to Cure Calpain 3 (C3) is pleased to announce that we are funding a new research grant to Dr. Kathryn Wagner. Dr. Wagner, Director of the Center for Genetic Muscle Disorders at the Kennedy Krieger Institute and Professor of Neurology and Neuroscience at the Johns Hopkins School of Medicine, will investigate “Targeting Mss51 as…
Read More